RxDoctor Payments Data

Tomika Washington, APRN

Psychiatric/Mental Health · Olive Branch, MSNPI 1104309178

Payments from drug & device makers

$1,523in general payments, 2019–2025

Across 58 payments — averaging $26.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$240
  • AbbVie$192
  • Lundbeck LLC$157
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$149
  • Otsuka America Pharmaceutical, Inc.$145
  • Vanda Pharmaceuticals Inc.$123
  • plus $518 from 10 others

What the payments were for

  • Food & beverage$1,520100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,523 in reported general payments places this provider in the 65th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$13,567
Medicare patients
33
Services billed
169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HetliozTasimelteon20$447,609
AustedoDeutetrabenazine15$104,745
VraylarCariprazine Hcl12$16,670
Trazodone Hcl74$2,949
Aripiprazole46$1,348
Quetiapine Fumarate35$1,342
Duloxetine Hcl70$1,157
Haloperidol11$844
Amitriptyline Hcl24$791
Buspirone Hcl29$765
Fluvoxamine Maleate16$761
Bupropion XlBupropion Hcl48$717
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine30$621
Oxcarbazepine17$578
Hydroxyzine Hcl27$479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Hetlioz$123$447,60920 claims
Teva Pharmaceuticals USA, Inc.Austedo$240$104,74515 claims
AbbVieVraylar$192$16,67012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Olive Branch

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →